Yashica Pharmaceuticals
Yashica Pharmaceuticals
Yashica Pharmaceuticals

Yashica Pharmaceuticals


Yashica PharmaceuticalsYashica Pharmaceuticals

Home » Drug Intermediates

Drug Intermediates

We are one of the leading manufacturer and supplier of a wide range of Drug Intermediates like: 3(3-Chloropropyl)-2,3 dihydro 1H benzimidazol -2-one, 8-Chloro-6,11 dihydro-11-(1-methyl-4-pipyridinyl)-5H benzo [5,6] cyclohepta [1,2b] pyridin -11-ol, Dibenzosuberone, N-Methyl-4-chloro piperidine, Formamidine Acetate, 3-Methylamino-propionitrile. These are used to preform drug interaction activity which formed in new Chemical Products. Our range of drug intermediates is appreciated for its purity and effectiveness.
Name of Product CAS NO.
3(3-Chloropropyl)-2,3 dihydro 1H benzimidazol -2-one 62780-89-6
5-Chloro 2,3 dihydro -1- (4-piperidinyl) -1H- benzimidazol  - 2 -one 53789-28-0
3(2-(3-Chloro phenyl)ethyl) cyano pyridine 31255-55-7
8-Chloro-5,6 dihydro(1H)-benzo[5,6] cyclohepta
(1,2b) pyridin -11-one
8-Chloro-6,11 dihydro-11-(1-methyl-4-pipyridinyl)-5H benzo [5,6]  cyclohepta [1,2b] pyridin -11-ol 38089-93-9
11-[(N-methyl)-4-piperidylidene]-8chloro-6, 11-dihydro-5H-benzo [5,6]cyclohepta (1,2b) Pyridine (Methyl Loratadine) 38092-89-6
3(2-(3-Chloro phenyl)ethyl) cyano pyridine 255861-48-4
N-Methyl-4-chloro piperidine 5570-77-4
Dibenzosuberone 1210-35-1
3-(Di Methyl amino) propylchloride HCl 5407-04-5
2-Butyl-4-chloro-5-formyl imidazole 857-96-9
2n-Butyl-4-chloro-[1-(2’-cyanobiphenyl-4-yl) methyl]-5-(hydroxymethyl) -imidazole 114772-55-3
2-(chloromethyl)-4-methoxy-3, 5-dimethylpyridine hydrochloride 86604-75-3
3,4 Dimethoxy-2-chloromethyl pyridine Hydrochloride 72830-09-2
2-(Chloromethyl)-3-methyl-4-(2,2,2-Tri fluoro ethoxy) pyridine Hydrochloride 127337-60-4
2-[4-(aminomethyl)phenoxy]-N,N-dimethyl ethanamine 127337-60-4
(S)-(+)N,N-Dimethyl-3-(1-napthalenyloxy)-3-(2-thieyl)propanamine 132335-47-8
(S)-(-)N,N-dimethyl-3-hydroxy 3-(2-thieyl)propanamine 132335-44-5
2-Chloro-N-(2-cyclo propylamino-4-methyl-3-pyridine carboxamde 133627-47-1
2-Chloro-N-(2-chloro-4-methyl-3-pyridine carboxamde 133627-46-0
3-amino-2-Chloro-4-methyl pyride 133627-45-9
1-[2(2-Hydroxy ethoxy) ethyl]Piperazine 13349-82-1
N-[dibenzo-[b,f][1,4]thiazepin-11-Y1] Piperazine Hyderachloride 11974-74-4
Dibenzo-[b,f][1,4]Thiazepin-11(10H)-one 3159-07-7
1-(2,3-Dichlorophenyl)piperazine hydrochloride 119532-26-2
1-(4-methoxy phenyl)piperazine dihydrocholoride 38869-47-5
2,4-Dihydro-4-[4-[(4-methoxy phenyl)-1-piperazinyl]phenyl]-2-(1-methylpropyl)-3H-1,2,4 triazol-3-one -
2,4-Dihydro-4-[4-[(4-Hydroxy phenyl)-1-piperazinyl]phenyl]-2-(1-methylpropy)-3H-1,2,4 triazol-3-one 89848-21-5
Cis[2-(Bromomethyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl]methyl benzoate 61397-56-6
Cis-(2,4-(dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl-methyl)1,3-dioxolan-4-yl]methyl p-Toluenesulfonate 103661-14-9
Cis-(2,4-(dichlorophenyl)-2-(1H-1,2,4-triazol-1-yl-methyl)1,3-dioxolan-4-yl]methyl methanesulfonate 67914-86-7
Formamidine Acetate 3473-63-0
4-(4-hydroxyphenyl)-1-(1-methylethyl)piperazine 67914-97-0]
1-(4-Chlorophenyl)-N-Formyl-a-(2-Methylpropyl)Cyclobutane Methanamine 67914-97-0
1-(4-Chlorophenyl)-a-(2-Methylpropyl)Cyclobutane Methanamine Hydrochloride 84484-78-6
7-Hydroxy-3,4-dihydro-1H-quinolin-2-one(OR) 7-Hydroxy-3,4-Dihydro Carbostyril 22246-18-0
7-(4-Bromobutoxy)-1,2,3,-tetrahydroquinoline-2-one -
D-(-)-Diethyl tartrate 13811-71-7
2-[[[4-(3-Methoxy Propoxy)-3-Methyl-2Pyridyl]Methyl]Thio]-1H-Benzimidazole 117977-21-6
2-Chloromethyl-4-(3-Methoxy Propoxy)-3-methyl Pyridine Hydrochloride 153259-31-5
2-Choloromethy-3-methyl-4-(2,2,2-trifluroethoxy)pyridine hydrochloride 127337-60-4
3-Methylamino-propionitrile 693-05-0
3-[(4-Amino-6,7-dimethoxy-quinazolin-2-yl)-methyl-amino]-propionitrile -
Tetrahydro-furan-2-carboxylic acid {3-[(4-amino-6,7 dimethoxy-quinazolin-2-yl) meyl-amino]propyl}-amide[Alfuzosin Base] 81403-80-7
1-[(2,3-Dihyro-1,4-benzodioxan-2-yl) carbonyl] piperazine 70918-00-2
1H-Benzimidazole-2-n-propyl-4-methyl-6-(1'methyl benzimidazole-2'yl) 152628-02-9]
4,4'-Diiodobiphenyl 3001-15-8
4,4'-Dibromobiphenyl 92-86-4

Yes! I am Interested

Piperacillin & Tazobactam For Injections

  • Each vial contains: piperacillin sodium USP, Eq. to piperacillin 4 g, tazobactam sodium, Eq. to tazobactam 0.5 g
Pharmacological classification:
  • Antibacterial
Mechanism of action:
  • Piperacillin, a broad spectrum, semisynthetic penicillin exerts bactericidal activity by inhibition of both septum and cell wall synthesis.
  • Tazobactam, a beta-lactam structurally related to penicillins, is an inhibitor of many beta- lactamases, which commonly cause resistance to penicillins and cephalosporins but it does not inhibit AmpC enzymes or metallo beta-lactamases.
  • Tazobactam extends the antibiotic spectrum of Piperacillin to include many beta-lactamase- producing bacteria that have acquired resistance to Piperacillin alone.
Indications and usage:
  • Yashipiptaz is used in the management of neutropenic patients with fever suspected to be due to a bacterial infection. Yashipiptaz is indicated for the treatment of the following infections in adults and children over 2 years of age
  • Adults and adolescents:
  • Severe pneumonia including hospital-acquired and ventilator-associated pneumonia
  • Complicated urinary tract infections (including pyelonephritis)
  • Complicated intra-abdominal infections
  • Complicated skin and soft tissue infections (including diabetic foot infections)
  • Children 2 to 12 years of age: Complicated intra-abdominal infections
Dosage and administration:
  • Yashipiptaz is administered by intravenous injection (over 30 minutes). The dose and frequency of Yashipiptaz depends on the severity and localization of the infection and expected pathogens.
  • Adult and adolescent patients:
  • For Infections: The usual dose of 4g piperacillin /0.5g tazobactam is given every eight hours.
  • For nosocomial pneumonia & bacterial infections in neutropenic patients: Recommended dose of 4g piperacillin /0.5g tazobactam is every six hours. This regimen may also be applicable to treat patients with other indicated infections when particularly severe.
  • For patients on haemodialysis, one additional dose of piperacillin/tazobactam 2g/0.25g should be administered following each dialysis period. No dose adjustment is required for the elderly with normal renal function or creatinine clearance values above 40 mL/min.
  • Children: YASHIPIPTAZ is not recommended for children below 2 years age.
  • Neutropenic children with fever suspected due to bacterial infections: 80mg
  • Piperacillin/10mg tazobactam per kg body weight, every six hours; not to exceed the maximum 4g /0.5g per dose over 30 minutes.
  • Complicated intra-abdominal infections: 100mg piperacillin/12.5mg tazobactam per kg body weight, every eight hours; not to exceed the maximum 4g/0.5g per dose over 30 minutes.
  • Creatinine Clearance = 50 mg/mL: 70mg piperacillin/8.75mg tazobactam per kg body weight, every eight hours.
  • For children on haemodialysis, one additional dose of 40mg piperacillin /5mg tazobactam per kg should be administered following each dialysis period.

Yashica Pharmaceuticals

Our Product Range :     Active Pharmaceuticals Ingredients |Drug Intermediates | Finished Formulation

Home|About Us|Our Product Range|Media Gallery|Contact Us|Enquiry

Member INDIAMART© Yashica Pharmaceuticals Private Limited. All Rights Reserved (Terms of Use)
Developed and Managed by IndiaMART InterMESH Limited

Looking for Product Name ?


Send SMS Enquiry

*Please Enter Requirment

*Please Enter valid Mobile Number

*Please Enter Proper Name